Galmed Pharmaceuticals (GLMD) Stock: Buy, Sell, or Hold?
GLMD - Galmed Pharmaceuticals Ltd.
$4.63
0.80 (21.05%)
▲
5d:
+17.96%
30d:
+680.64%
90d:
+787.31%
WAIT
LOW Confidence
Analysis Updated: Sep 9, 2026 12:00 AM ET
Earnings: Aug 27, 2026
0d
Get Alerted When GLMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GLMD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GLMD shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: GLMD is currently trading at $4.63, which is considered extended relative to its 30-day fair value range of $0.95 to $4.55.
Technical Outlook: Technically, GLMD is in a strong uptrend. The price is approaching resistance at $4.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 21.0% recently.
Market Sentiment: GLMD scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+159.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GLMD is in a strong uptrend. The price is approaching resistance at $4.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 21.0% recently.
Market Sentiment: GLMD scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+159.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.95 -
$4.55
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+21.0%)
- BULLISH: Trading 159.2% below Wall St target ($12.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.95 -
$4.55
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.74
Resistance Level
$4.63
Current Trend
Strong Uptrend
Technical data as of
Sep 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.64
Wall Street Target
$12.00
(+159.2%)
Share & Embed Analysis
Last updated: September 13, 2026 10:08 AM ET
Data refreshes hourly during market hours. Next update: 11:08 AM
Data refreshes hourly during market hours. Next update: 11:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
